{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=83", "query": { "intervention": "Injectable Placebo", "page": 83 }, "page_size": 10 }, "pagination": { "page": 83, "page_size": 10, "total_count": 4225, "total_pages": 423, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=84&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=82&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T16:33:11.014Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00976937", "title": "24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Lixisenatide Placebo", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Sitagliptin Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 319, "start_date": "2009-08", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2016-10-11", "last_synced_at": "2026-11-05T16:33:11.014Z", "location_count": 21, "location_summary": "Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Paramount", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00976937" }, { "nct_id": "NCT00344448", "title": "Pilot Study of Raptiva to Treat Sjogren's Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sjogren's Syndrome" ], "interventions": [ { "name": "Raptiva", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Dental and Craniofacial Research (NIDCR)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2006-06", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2015-12-21", "last_synced_at": "2026-11-05T16:33:11.014Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00344448" }, { "nct_id": "NCT03991936", "title": "Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Nail Psoriasis", "Nail Diseases" ], "interventions": [ { "name": "Placebos", "type": "DRUG" }, { "name": "Triamcinolone Acetonide 2.5 mg/mL", "type": "DRUG" }, { "name": "Triamcinolone Acetonide 5.0 mg/mL", "type": "DRUG" }, { "name": "Triamcinolone Acetonide 7.5 mg/mL", "type": "DRUG" }, { "name": "Triamcinolone Acetonide 10 mg/mL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2020-03-11", "completion_date": "2023-03-29", "has_results": true, "last_update_posted_date": "2024-03-27", "last_synced_at": "2026-11-05T16:33:11.014Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03991936" }, { "nct_id": "NCT07143448", "title": "A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "HS235", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "35Pharma Inc., a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2026-08-19", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-10-30", "last_synced_at": "2026-11-05T16:33:11.014Z", "location_count": 3, "location_summary": "Tampa, Florida • Boston, Massachusetts • Providence, Rhode Island", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT07143448" }, { "nct_id": "NCT03307915", "title": "A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Immunodeficiency Virus" ], "interventions": [ { "name": "Ad26.Mos4.HIV", "type": "BIOLOGICAL" }, { "name": "MVA-Mosaic", "type": "BIOLOGICAL" }, { "name": "Clade C gp140 + Mosaic gp140", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 25, "start_date": "2018-03-05", "completion_date": "2021-11-05", "has_results": false, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-11-05T16:33:11.014Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03307915" }, { "nct_id": "NCT06395948", "title": "A Study Evaluating APG777 in Atopic Dermatitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "APG777", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apogee Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 470, "start_date": "2024-04-29", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-05T16:33:11.014Z", "location_count": 29, "location_summary": "Fountain Valley, California • Los Angeles, California • San Diego, California + 25 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Coral Gables", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06395948" }, { "nct_id": "NCT01125748", "title": "A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Allergic Asthma" ], "interventions": [ { "name": "Omalizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Asthma therapies", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "17 Years to 70 Years" }, "enrollment_count": 176, "start_date": "2010-05", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2014-10-15", "last_synced_at": "2026-11-05T16:33:11.014Z", "location_count": 100, "location_summary": "Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 87 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01125748" }, { "nct_id": "NCT03949855", "title": "Belimumab With Rituximab for Primary Membranous Nephropathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Membranous Nephropathy", "Nephrotic Syndrome" ], "interventions": [ { "name": "Belimumab", "type": "DRUG" }, { "name": "Placebo for Belimumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 58, "start_date": "2020-03-06", "completion_date": "2030-03-01", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-11-05T16:33:11.014Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03949855" }, { "nct_id": "NCT00419263", "title": "Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Peramivir 150 mg", "type": "DRUG" }, { "name": "Peramivir 300 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioCryst Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 344, "start_date": "2007-01", "completion_date": "2007-09", "has_results": true, "last_update_posted_date": "2015-02-12", "last_synced_at": "2026-11-05T16:33:11.014Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" }, { "city": "Carmichael", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00419263" }, { "nct_id": "NCT04508504", "title": "PENG Block for Arthroscopic Hip Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Postoperative Pain", "Hip Arthroscopy" ], "interventions": [ { "name": "Preop PENG block", "type": "PROCEDURE" }, { "name": "Placebo block", "type": "PROCEDURE" }, { "name": "Ropivacaine 0.5% Injectable Solution", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2020-12-01", "completion_date": "2022-02-08", "has_results": false, "last_update_posted_date": "2022-03-25", "last_synced_at": "2026-11-05T16:33:11.014Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04508504" } ] }